KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Non-Current Assets (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Non-Current Assets for 16 consecutive years, with $76.6 billion as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Non-Current Assets rose 3.54% year-over-year to $76.6 billion, compared with a TTM value of $297.2 billion through Sep 2024, up 0.93%, and an annual FY2023 reading of $74.1 billion, up 3.08% over the prior year.
  • Non-Current Assets was $76.6 billion for Q3 2024 at Thermo Fisher Scientific, up from $73.0 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $76.6 billion in Q3 2024 and bottomed at $45.8 billion in Q2 2020.
  • Average Non-Current Assets over 5 years is $63.9 billion, with a median of $72.5 billion recorded in 2022.
  • The sharpest move saw Non-Current Assets soared 8409.26% in 2020, then fell 4.11% in 2022.
  • Year by year, Non-Current Assets stood at $47.1 billion in 2020, then surged by 59.27% to $75.0 billion in 2021, then fell by 4.11% to $71.9 billion in 2022, then rose by 3.08% to $74.1 billion in 2023, then grew by 3.3% to $76.6 billion in 2024.
  • Business Quant data shows Non-Current Assets for TMO at $76.6 billion in Q3 2024, $73.0 billion in Q2 2024, and $73.5 billion in Q1 2024.